Published in Cardiovascular Business Week, November 15th, 2005
The post-approval studies were intended to evaluate the long-term safety and efficacy of the Beta-Cath System in patients who were enrolled in the StarT and StarT 40/20 trials for the treatment of in-stent restenosis of native coronary arteries beyond the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.